| Literature DB >> 27927163 |
Patricia Cristina Saldanha Ribeiro1, Andrea Souza Monteiro1, Sirlei Garcia Marques2, Sílvio Gomes Monteiro1, Valério Monteiro-Neto1, Martina Márcia Melo Coqueiro1, Ana Cláudia Garcia Marques3, Rosimary de Jesus Gomes Turri4, Simone Gonçalves Santos5, Maria Rosa Quaresma Bomfim6.
Abstract
BACKGROUND: Bacteria that produce Klebsiella pneumoniae carbapenemases (KPCs) are resistant to broad-spectrum β-lactam antibiotics. The objective of this study was to phenotypically and genotypically characterize the antibiotic susceptibility to carbapenems of 297 isolates recovered from clinical samples obtained from inpatients at 16 hospitals in São Luis (Maranhão, Brazil).Entities:
Keywords: Enterobacterial repetitive intergenic consensus PCR (ERIC-PCR); Klebsiella pneumoniae carbapenemases (KPCs); Multidrug-resistance (MDR); bla KPC gene variants
Mesh:
Substances:
Year: 2016 PMID: 27927163 PMCID: PMC5142414 DOI: 10.1186/s12879-016-2072-3
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Distribution of Gram-negative bacilli obtained in São Luis, MA, from June 2012 to July 2013
| Bacterial species | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Origina |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total (%) |
| H01 | 37 | 0 | 8 | 2 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 24 | 0 | 1 | 0 | 78 (26.3) |
| H02 | 15 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 18 (6.1) |
| H03 | 6 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 (2.4) |
| H04 | 3 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 (1.3) |
| H05 | 10 | 0 | 1 | 0 | 0 | 3 | 1 | 0 | 2 | 0 | 3 | 6 | 0 | 0 | 0 | 26 (8.8) |
| H06 | 3 | 1 | 8 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 15 (5.1) |
| H07 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (0.3) |
| H08 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 (0.3) |
| H09 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 1 | 0 | 5 | 0 | 0 | 0 | 9 (3.0) |
| H10 | 44 | 0 | 16 | 1 | 0 | 1 | 3 | 0 | 0 | 1 | 0 | 25 | 0 | 1 | 1 | 93 (31.3) |
| H11 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 3 (1.0) |
| H12 | 5 | 0 | 5 | 1 | 0 | 2 | 4 | 2 | 1 | 0 | 1 | 14 | 0 | 0 | 0 | 35 (11.8) |
| H13 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 (1.0) |
| H14 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (0.3) |
| H15 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 (0.7) |
| H16 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (0.3) |
| Total | 128 | 1 | 42 | 5 | 1 | 9 | 19 | 3 | 3 | 2 | 5 | 75 | 1 | 2 | 1 | 297 (100) |
aPublic hospitals (H01 to H10 and H13 to H16); Private hospitals (H11 and H12)
Antibiotic resistance profiles and minimal inhibitory concentrations for fermentative bacilli species
| fermentative gram-negative bacilli | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Antibiotics |
|
|
|
|
|
|
|
|
|
| ||||||||||
| % | MIC | % | MIC | % | MIC | % | MIC | % | MIC | % | MIC | % | MIC | % | MIC | % | MIC | % | MIC | |
| amikacin | 12 | ≥64 | 5.3 | ≥64 | 33.3 | ≥64 | 80.0 | ≥64 | 0.0 | 16 | 33.3 | ≥64 | 0.0 | 16 | 0.0 | 4 | 0.0 | ≤2 | 0.0 | 4 |
| ampicillin | 100 | ≥32 | 100 | ≥32 | 100 | ≥32 | 100 | ≥32 | 100 | ≥32 | 100 | ≥32 | 100 | ≥32 | 100 | ≥32 | 100 | ≥32 | 100 | ≥32 |
| amp/sulbacb | 100 | ≥32 | 100 | ≥32 | 100 | ≥32 | 100 | ≥32 | 100 | ≥32 | 100 | ≥32 | 100 | ≥32 | 100 | ≥32 | 100 | ≥32 | 100 | ≥32 |
| aztreonam | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 |
| cephalothin | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 |
| cefepime | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 |
| cefotaxime | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 |
| cefoxitin | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 |
| ceftazidime | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 |
| ciprofloxacin | 93.3 | ≥4 | 89.5 | ≥4 | 55.6 | ≥4 | 0.0 | ≤0.25 | 66.7 | ≥4 | 66.7 | ≥4 | 100 | ≥4 | 100 | ≥4 | 50.0 | ≥4 | 0.0 | ≤0.5 |
| polymyxin B | 10.7 | 64 | 0 | ≤0.5 | 0.0 | ≤0.5 | 100 | ≥16 | 0.0 | ≤0.5 | 100 | ≥16 | 100 | ≥16 | 100 | ≥16 | 0.0 | ≤0.5 | NTd | NTd |
| gentamicin | 52 | ≥16 | 68.4 | ≥16 | 11.1 | ≥16 | 40.0 | ≥16 | 33.3 | ≥16 | 66.7 | ≥16 | 100 | ≥16 | 0.0 | ≤1 | 50.0 | ≥16 | 0.0 | ≤1 |
| imipenem | 85.3 | ≥32 | 42.1 | ≥32 | 88.9 | ≥32 | 80.0 | ≥16 | 33.3 | ≥16 | 100 | ≥32 | 100 | ≥16 | 100 | ≥16 | 0.0 | ≤1 | 100 | ≥16 |
| meropenem | 84 | ≥32 | 42.1 | ≥32 | 88.9 | ≥32 | 80.0 | ≥16 | 33.3 | ≥16 | 66.7 | ≥32 | 50.0 | ≥16 | 100 | ≥16 | 0.0 | ≤0.25 | 100 | ≥16 |
| ertapenem | 100 | ≥32 | 100 | ≥32 | 88.9 | ≥32 | 100 | ≥8 | 100 | ≥8 | 100 | ≥32 | 100 | ≥8 | 100 | ≥8 | 100 | ≥8 | 100 | ≥8 |
| piper/tazobc | 100 | ≥128 | 94.7 | ≥128 | 88.9 | ≥128 | 100 | ≥128 | 100 | ≥128 | 66.7 | ≥128 | 100 | ≥128 | 100 | ≥128 | 100 | ≥128 | 0.0 | 16 |
| tigecycline | 21.3 | ≥8 | 52.6 | ≥8 | 22.2 | ≥8 | 40.0 | ≥8 | NTd | NTd | 100 | ≥8 | 100 | 4 | 0.0 | 2 | 0.0 | ≤0.5 | NTd | NTd |
| 75 | 19 | 9 | 5 | 3 | 3 | 2 | 1 | 2 | 1 | |||||||||||
a Family Aeromonadaceae
b amp/sulbac = ampicillin/sulbactam
c piper/tazob = piperacillin-tazobactam
d NT = non-tested
Antibiotic resistance profiles and minimal inhibitory concentrations for non-fermentative bacilli species
| non-fermentative gram-negative bacilli | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Antibiotics |
|
|
|
|
| |||||
| % | MIC | % | MIC | % | MIC | % | MIC | % | MIC | |
| amikacin | 22.7 | ≥64 | 0.0 | 4 | 28.6 | ≥64 | 0.0 | ≤2 | 0.0 | 16 |
| ampicillin | 100 | ≥32 | 100 | ≥32 | 100 | ≥32 | 100 | ≥32 | 100 | ≥32 |
| amp/sulbaca | 72.7 | ≥32 | 100 | ≥32 | 100 | ≥32 | 100 | ≥32 | 100 | ≥32 |
| aztreonam | 100 | ≥64 | 100 | ≥64 | NTc | NTc | NTc | NTc | NTc | NTc |
| cephalothin | 100 | ≥64 | 100 | ≥64 | NTc | NTc | 100 | ≥64 | 100 | ≥64 |
| cefepime | 97.7 | ≥64 | 100 | ≥64 | 64.3 | ≥64 | 100 | ≥64 | 60.0 | ≥64 |
| cefotaxime | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 | NTc | NTc | 100 | ≥64 |
| cefoxitin | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 |
| ceftazidime | 99.2 | ≥64 | 100 | ≥64 | 71.4 | ≥64 | 100 | ≥64 | 80.0 | ≥64 |
| ciprofloxacin | 96.9 | ≥4 | 0.0 | ≤0.5 | 69.0 | ≥4 | 100 | ≥4 | 40.0 | ≥4 |
| polymyxin B | 0.0 | ≤0.5 | 0.0 | ≤0.5 | 0.0 | ≤0.5 | 0.0 | ≤0.5 | 0.0 | ≤0.5 |
| gentamicin | 53.1 | ≥16 | 100 | ≥16 | 59.5 | ≥16 | 0.0 | ≤1 | 20.0 | ≥16 |
| imipenem | 100 | ≥16 | 100 | ≥16 | 100 | ≥16 | 100 | ≥16 | 100 | ≥16 |
| meropenem | 100 | ≥16 | 100 | ≥16 | 100 | ≥16 | 100 | ≥16 | 100 | ≥16 |
| ertapenem | NTc | NTc | NTc | NTc | NTc | NTc | NTc | NTc | NTc | NTc |
| piper/tazobb | 100 | ≥128 | 100 | ≥128 | 78.6 | ≥128 | 0.0 | 16 | 60.0 | ≥128 |
| tigecycline | 0.8 | 4 | NTc | NTc | 100 | ≥8 | 100 | ≥8 | 100 | ≥8 |
| Total | 128 | 1 | 42 | 1 | 5 | |||||
aamp/sulbac = ampicillin/sulbactam
bpiper/tazob = piperacillin-tazobactam
cNT = non-tested
Association of the bla gene and the modified Hodge test with Enterobacteriaceae species
| Enterobacteria | Total |
| MHTa |
|
|
|---|---|---|---|---|---|
| No. (%) | No. (%) | No. (%) | |||
|
| 9 | 6 (66.7) | 7 (77.8) | 5 (55.6) | 0.0001 |
|
| 19 | 6 (31.6) | 7 (36.8) | 4 (21.1) | |
|
| 2 | 1 (50.0) | 0 (0) | 0 | |
|
| 75 | 60 (80.0) | 60 (80.0) | 49 (65.3) | |
|
| 3 | 1 (33.3) | 1 (33.3) | 1 (33.3) | |
|
| 3 | 0 (0) | 1 (33.3) | 0 (0) | |
|
| 2 | 2 (100) | 2 (100) | 2 (100) | |
|
| 1 | 1 (100) | 1 (100) | 1 (100) | |
|
| 5 | 2 (40.0) | 3 (60.0) | 2 (40.0) | |
| Total | 119 | 79 (66.4) | 82 (68.9) | 64 (53.7) |
aMHT, modified Hodge test; P < 0.0001, Nonparametric chi-square test of independence
Frequency of antimicrobial-resistant microorganisms harboring blaKPC
| % antibiotic resistance strains with | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Species | AMI | AMP | ASB | ATM | CFL | CEF | CTX | CFO | CAZ | CIP | POL | GEN | IMP | MER | ERT | PTZ | TIG | No. of |
|
| 23.8 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0.0 | 47.6 | 100 | 100 | NTb | 100 | 0.0 | 21 |
|
| 50.0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 33.3 | 0.0 | 16.7 | 83.3 | 83.3 | 83.3 | 83.3 | 33.3 | 6 |
|
| 20.0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0.0 | 60.0 | 100 | 100 | 100 | 100 | 40.0 | 6 |
|
| 0.0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0.0 | 100 | 0.0 | 0.0 | 100 | 100 | NTa | 1 |
|
| 13.6 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 83.1 | 11.9 | 52.5 | 94.9 | 88.1 | 100 | 100 | 20.3 | 60 |
|
| 0.0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0.0 | 100 | 100 | 100 | 100 | 100 | NTa | 1 |
|
| 0.0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 50.0 | 100 | 100 | 100 | 2 |
|
| 0.0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0.0 | 100 | 100 | 100 | 100 | 0.0 | 1 |
|
| 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0.0 | 100 | 50.0 | 100 | 100 | 100 | 100 | 50.0 | 2 |
aAMI, amikacin (30 μg); AMP, ampicillin (10 μg); ASB, ampicillin/sulbactam (10/10 μg); ATM, aztreonam (30 μg); CFL, cephalothin (30 μg); CEF, cefepime (30 μg), CTX, cefotaxime (30 μg); CFO, cefoxitin (30 μg); CAZ, ceftazidime (30 μg), CIP, ciprofloxacin (5 μg); ERT, ertapenem (10 μg); GEN, gentamicin (10 μg); IMP, imipenem (10 μg); MER, meropenem (10 μg); and PTZ, piperacillin/tazobactam (100/10 μg); POL, Polymixin B (300 U); TIG, Tigecicline (15 μg)
bNT = non-tested
Fig. 1Agarose gel electrophoresis (2%) of the PCR products with primers specific for the bla OXA-51 gene in isolated evaluated in this study. Lane 1: Molecular pattern: 100 bp marker (Promega Corporation, Madison, USA); Lane 2: PC (positive control)/Acinetobacter baumannii ATCC19606; Lanes 3–19: Clinical isolates of A. baumannii harboring bla OXA-51 gene (353 bp), and Lane 20: Clinical isolates of A. ursingii
Fig. 2Dendrogram showing the genetic relatedness of 75 Klebsiella pneumoniae isolates. Cluster analysis of enterobacterial repetitive intergenic consensus PCR (ERIC-PCR) fingerprinting patterns using the DICE similarity coefficient and the UPGMA cluster method. The scale indicates the percentage of genetic similarity
Fig. 3Dendrogram showing the genetic relatedness of 45 other isolates from the Enterobacteriaceae family. Cluster analysis of enterobacterial repetitive intergenic consensus PCR (ERIC-PCR) fingerprinting patterns using the DICE similarity coefficient and the UPGMA cluster method. The scale indicates the percentage of genetic similarity
Fig. 4Dendrogram showing the genetic relatedness of 129 Acinetobacter spp. isolates. Cluster analysis of enterobacterial repetitive intergenic consensus PCR (ERIC-PCR) fingerprinting patterns using the DICE similarity coefficient and the UPGMA cluster method. The scale indicates the percentage of genetic similarity
Fig. 5Dendrogram showing the genetic relatedness of Pseudomonas spp. isolates. Cluster analysis of enterobacterial repetitive intergenic consensus PCR (ERIC-PCR) fingerprinting patterns using the DICE similarity coefficient and the UPGMA cluster method. The scale indicates the percentage of genetic similarity